Cynosure Group’s C4 Therapeutics CCCC Stock Holding History

Cynosure Group’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,007	Closed	-$57K	–	370
2024 Q3	$57K	Buy	+10,007	New	+$60.2K	0.01%	369

Other funds holding CCCC

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cynosure Group's CCCC Position: Q4 2024 in Review

Cynosure Group sold out of C4 Therapeutics (CCCC) in Q4 2024, closing a stake of 10,007 shares — an estimated $57K sold.

Cynosure Group first reported a position in CCCC in Q3 2024 and held it in 1 quarter. The position peaked at $57K in Q3 2024. 113 funds tracked by Wall St. Rank hold CCCC as of Q4 2024.

Cynosure Group reported no remaining C4 Therapeutics position as of Q4 2024 after selling out during the quarter.
Cynosure Group sold 10,007 C4 Therapeutics shares in Q4 2024, an estimated $57K.
Cynosure Group first reported a position in C4 Therapeutics in Q3 2024 and held it in 1 quarter.
Cynosure Group's C4 Therapeutics position peaked at $57K in Q3 2024.
113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2024.

Based on Cynosure Group's 13F filing for Q4 2024, filed 12 Feb 2025.